{"id":"ranibizumab-plus-photodynamic-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Photopsia"},{"rate":null,"effect":"Vision blurred"},{"rate":"0.05–0.1","effect":"Endophthalmitis"}]},"_chembl":{"chemblId":"CHEMBL1201825","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ranibizumab is a monoclonal antibody fragment that inhibits VEGF-A, preventing neovascularization and vascular leakage in the retina. Photodynamic therapy (PDT) involves intravenous administration of a photosensitizing agent followed by laser activation to selectively destroy abnormal choroidal neovascularization. The combination targets both the angiogenic driver (VEGF) and the pathological vasculature directly.","oneSentence":"Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth, while photodynamic therapy uses light-activated drugs to destroy diseased retinal tissue.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:49.788Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Wet age-related macular degeneration (AMD)"},{"name":"Choroidal neovascularization secondary to pathologic myopia"}]},"trialDetails":[{"nctId":"NCT00930189","phase":"PHASE2, PHASE3","title":"Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-04","conditions":"Subfoveal Choroidal Neovascularization","enrollment":""},{"nctId":"NCT04075136","phase":"PHASE4","title":"Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2023-03-30","conditions":"Exudative Age Related Macular Degeneration","enrollment":""},{"nctId":"NCT01469156","phase":"PHASE1, PHASE2","title":"Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Southeast Retina Center, Georgia","startDate":"2011-09","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":20},{"nctId":"NCT00473642","phase":"PHASE4","title":"Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Oklahoma State University Center for Health Sciences","startDate":"2007-05","conditions":"Age-Related Maculopathy, Choroidal Neovascularization","enrollment":31},{"nctId":"NCT01846273","phase":"PHASE4","title":"Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-08-07","conditions":"Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy","enrollment":321},{"nctId":"NCT02218177","phase":"","title":"Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2014-08","conditions":"Age Related Macular Degeneration","enrollment":30},{"nctId":"NCT00423189","phase":"PHASE4","title":"Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration","status":"TERMINATED","sponsor":"David M. Brown, M.D.","startDate":"2007-01","conditions":"Age-Related Macular Degeneration","enrollment":7},{"nctId":"NCT01666236","phase":"PHASE4","title":"Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy","status":"WITHDRAWN","sponsor":"Federal University of São Paulo","startDate":"2012-09","conditions":"Choroidal Neovascularization, Retinal Pigment Epithelial Detachment","enrollment":""},{"nctId":"NCT01319188","phase":"PHASE4","title":"Ranibizumab and the Risk of Arterial Thromboembolic Events","status":"TERMINATED","sponsor":"Ural State Medical University","startDate":"2010-06","conditions":"Age-related Macular Degeneration, Coronary Artery Disease, Cerebrovascular Disorders","enrollment":380},{"nctId":"NCT00061594","phase":"PHASE3","title":"A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2003-05","conditions":"Macular Degeneration","enrollment":426},{"nctId":"NCT01968486","phase":"PHASE1","title":"Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2012-06","conditions":"Myopia, Degenerative","enrollment":60},{"nctId":"NCT00056823","phase":"PHASE1, PHASE2","title":"Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2003-03","conditions":"Age-Related Maculopathy","enrollment":168},{"nctId":"NCT01325181","phase":"PHASE1, PHASE2","title":"Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy","status":"COMPLETED","sponsor":"Jang Won Heo","startDate":"2009-07","conditions":"Chronic Central Serous Chorioretinopathy","enrollment":34},{"nctId":"NCT00570193","phase":"PHASE1, PHASE2","title":"Photodynamic and Pharmacologic Treatment of CNV","status":"COMPLETED","sponsor":"Mid-Atlantic Retina Consultations, Inc.","startDate":"2006-12","conditions":"Choroidal Neovascularization, Macular Degeneration","enrollment":41},{"nctId":"NCT00726973","phase":"NA","title":"Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)","status":"WITHDRAWN","sponsor":"Lahey Clinic","startDate":"2006-12","conditions":"Macular Edema","enrollment":""},{"nctId":"NCT01570608","phase":"PHASE3","title":"Lucentis KAV Study","status":"COMPLETED","sponsor":"The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery","startDate":"2007-03","conditions":"Age Related Macular Degeneration","enrollment":51},{"nctId":"NCT00680498","phase":"PHASE4","title":"Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment","status":"COMPLETED","sponsor":"Illinois Retina Associates","startDate":"2007-02","conditions":"Age-Related Macular Degeneration","enrollment":10},{"nctId":"NCT00492284","phase":"PHASE2","title":"Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)","status":"COMPLETED","sponsor":"QLT Inc.","startDate":"2007-07","conditions":"Choroidal Neovascularization, Macular Degeneration","enrollment":162},{"nctId":"NCT00433017","phase":"PHASE2, PHASE3","title":"Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)","status":"TERMINATED","sponsor":"Novartis","startDate":"2007-05","conditions":"Macular Degeneration, Choroidal Neovascularization","enrollment":255},{"nctId":"NCT00436553","phase":"PHASE3","title":"Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-02","conditions":"Macular Degeneration, Choroidal Neovascularization","enrollment":321},{"nctId":"NCT00674323","phase":"PHASE4","title":"Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-04","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":61},{"nctId":"NCT00390208","phase":"PHASE2","title":"Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Bay Area Retina Associates","startDate":"2006-08","conditions":"Age Related Macular Degeneration","enrollment":60},{"nctId":"NCT00413829","phase":"PHASE2","title":"Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2006-10","conditions":"Age Related Macular Degeneration","enrollment":20},{"nctId":"NCT00546936","phase":"PHASE2","title":"Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis","status":"UNKNOWN","sponsor":"Barnes Retina Institute","startDate":"2007-10","conditions":"Presumed Ocular Histoplasmosis (POHS)","enrollment":30},{"nctId":"NCT00429962","phase":"PHASE3","title":"Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2006-07","conditions":"Choroidal Neovascularization, Age-Related Macular Degeneration","enrollment":40},{"nctId":"NCT00813891","phase":"PHASE4","title":"Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2009-01","conditions":"Macular Degeneration, Visual Acuity","enrollment":180},{"nctId":"NCT00288561","phase":"PHASE2","title":"Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":"Age-Related Macular Degeneration (ARMD)","enrollment":""},{"nctId":"NCT00455871","phase":"NA","title":"Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD","status":"UNKNOWN","sponsor":"Barnes Retina Institute","startDate":"2007-04","conditions":"Age-Related Macular Degeneration","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":38,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lucentis","Visudyne"],"phase":"marketed","status":"active","brandName":"Ranibizumab plus Photodynamic therapy","genericName":"Ranibizumab plus Photodynamic therapy","companyName":"Illinois Retina Associates","companyId":"illinois-retina-associates","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth, while photodynamic therapy uses light-activated drugs to destroy diseased retinal tissue. Used for Wet age-related macular degeneration (AMD), Choroidal neovascularization secondary to pathologic myopia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}